Affordable Access

Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin.

  • Tardy, Bernard
  • Lecompte, Thomas
  • Boelhen, Françoise
  • Tardy-Poncet, Brigitte
  • Elalamy, Ismaïl
  • Morange, Pierre
  • Gruel, Yves
  • Wolf, Martine
  • François, Dominique
  • Racadot, Evelyne
  • Camarasa, Philippe
  • Blouch, Marie Thérèse
  • Nguyen, Françoise
  • Doubine, Sylvie
  • Dutrillaux, Fabienne
  • Alhenc-Gelas, Martine
  • Martin-Toutain, Isabelle
  • Bauters, Anne
  • Ffrench, Patrick
  • De Maistre, Emmanuel
  • And 6 more
Publication Date
Sep 01, 2006
External links


The antithrombotic efficacy of lepirudin in patients with heparin-induced thrombocytopenia (HIT) is compromised by an increased risk for bleeding. A retrospective observational analysis in 181 patients (median age, 67 years) with confirmed HIT treated in routine practice with lepirudin was performed to identify predictive factors for thrombotic and bleeding complications. Lepirudin was administered at a mean (+/- SD) dose of 0.06 +/- 0.04 mg/kg/h (compared with a recommended initial dose of 0.15 mg/kg/h). Mean activated partial thromboplastin time was greater than 1.5 times baseline value in 99.4% of patients. Median treatment duration was 7.7 days. Until discharge from the hospital, 13.8% and 20.4% of patients experienced a thrombotic or a major bleeding event, respectively. On multivariate analysis, mean lepirudin dose was not a significant predictive factor for thrombosis. In contrast, mean lepirudin dose greater than 0.07 mg/kg/h, long duration of lepirudin treatment, and moderate to severe renal impairment were significant positive factors for major bleeding. Overall, these results suggest that the recommended dose of lepirudin in patients with HIT is too high; the use of reduced doses may be safer with regard to bleeding risk and does not compromise antithrombotic efficacy.

Report this publication


Seen <100 times